Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
19.93
-0.63 (-3.06%)
At close: Dec 5, 2025, 4:00 PM EST
20.32
+0.39 (1.96%)
After-hours: Dec 5, 2025, 4:15 PM EST

Forte Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
11.715.4110.628.37.634.22
Upgrade
Research & Development
41.7421.1921.865.5913.8510
Upgrade
Operating Expenses
53.4436.632.4913.921.4914.23
Upgrade
Operating Income
-53.44-36.6-32.49-13.9-21.49-14.23
Upgrade
Interest & Investment Income
1.311.311.120.16--
Upgrade
Other Non Operating Income (Expenses)
0.14-0.19-0.11-0.15-0.22-0.21
Upgrade
EBT Excluding Unusual Items
-51.99-35.48-31.48-13.88-21.71-14.43
Upgrade
Pretax Income
-51.74-35.48-31.48-13.88-21.71-46.49
Upgrade
Net Income
-51.74-35.48-31.48-13.88-21.71-46.49
Upgrade
Net Income to Common
-51.74-35.48-31.48-13.88-21.71-46.49
Upgrade
Shares Outstanding (Basic)
1231110
Upgrade
Shares Outstanding (Diluted)
1231110
Upgrade
Shares Change (YoY)
538.39%130.90%81.61%24.45%89.81%249.05%
Upgrade
EPS (Basic)
-4.39-12.17-24.92-19.96-38.85-157.93
Upgrade
EPS (Diluted)
-4.39-12.17-24.92-19.96-38.85-157.93
Upgrade
Free Cash Flow
-44.57-30.78-28.79-8.19-16.68-18.42
Upgrade
Free Cash Flow Per Share
-3.78-10.56-22.80-11.77-29.85-62.59
Upgrade
EBITDA
-53.38-36.56-32.48-13.86-21.45-14.17
Upgrade
D&A For EBITDA
0.060.040.010.040.040.05
Upgrade
EBIT
-53.44-36.6-32.49-13.9-21.49-14.23
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.